The United States heparin market is driven by growing incidences of cardiovascular and thromboembolic disorders. Increasing demand for anticoagulant therapies, advancements in manufacturing processes, and rising healthcare expenditure are propelling growth. Additionally, focus on low molecular weight heparin and biosynthetic alternatives supports market expansion. https://www.imarcgroup.com/united-states-heparin-market